KEY DETAILS
Novo Nordisk's phase 1 trial, not yet recruiting, would test switching from maintenance tirzepatide to a new drug called zenagamtide.
A preprint, not yet peer reviewed, found that in routine practice most patients starting semaglutide or tirzepatide did not remain on therapy, reach a maintenance dose, and have weight documented through the first year.
A phase III trial published October 7, 2026 found HD1916, a chemically synthesized semaglutide injection, had equivalent body weight reductions to Wegovy, with a comparable safety profile.
Wampler v. Novo Nordisk Inc is a pending personal injury product liability case in the Eastern District of Pennsylvania, with its latest docket action dated October 8, 2026.
New York's A 9184 was reprinted as 9184A on October 9, 2026, and has had no votes.
Novo Nordisk has registered a phase 1 trial that would test switching patients from maintenance tirzepatide to a drug called zenagamtide, though it has not started recruiting yet. The other items below are also dated October 6 to 9, 2026, and include a court case and a New York bill about insurer, pharmacy benefit manager and pharmacy control whose description does not mention GLP-1 drugs.
Novo Nordisk A/S is sponsoring the study, which is phase 1 and was last updated October 9, 2026. It has not started recruiting yet. The trial would test which zenagamtide dose people can switch to from a maintenance dose of tirzepatide, with a planned enrollment of 60 adults with overweight or obesity, with or without type 2 diabetes. All participants will get tirzepatide and zenagamtide.
A preprint posted October 6, 2026 on medRxiv looked at what happens after people start these drugs in routine practice. It found that most patients who began semaglutide or tirzepatide did not remain on therapy, reach a maintenance dose, and have weight documented through the first year. The preprint has not been peer reviewed. Documented weight loss was greatest among patients who completed each step of care, and the preprint suggests continuation, dose escalation and monitoring as targets for improvement.
A multicenter phase III trial, published October 7, 2026 in Diabetes, Obesity and Metabolism, tested HD1916, a chemically synthesized semaglutide injection, against the reference product semaglutide sold as Wegovy. The published summary says HD1916 produced equivalent body weight reductions to Wegovy, with a comparable safety profile.
On the legal side, Wampler v. Novo Nordisk Inc is a personal injury product liability case. It is pending in the Eastern District of Pennsylvania, and its latest docket action is dated October 8, 2026.
In New York, Assembly bill A 9184 has 9 sponsors and was reprinted as 9184A on October 9, 2026. It has had no votes. The bill would limit overlapping control between insurance companies, pharmacy benefit managers and pharmacies, and it would require divestment of interests in one or more insurance companies and pharmacy benefit managers. It would also bar insurers, pharmacies and PBMs found in violation from receiving payment from certain state programs. It is still a bill, not a law, and its description does not mention GLP-1 drugs.
The trial registration, the lawsuit and the bill are all ongoing. The HD1916 trial and the preprint have already reported results, and the preprint has not been peer reviewed.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.